المؤلفون: Enrico Vasile, Carmelo Tibaldi, G. Leticia Leon, Elisa Giovannetti, Armida D'Incecco

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: Journal of Cancer Research and Clinical Oncology, 141(7), 1189-1194. Springer Verlag
Vasile, E, Tibaldi, C, Leon, G L, D'Incecco, A & Giovannetti, E 2015, ' Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients ', Journal of Cancer Research and Clinical Oncology, vol. 141, no. 7, pp. 1189-1194 . https://doi.org/10.1007/s00432-014-1880-3Test

مصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, CYP1B1, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Single-nucleotide polymorphism, Docetaxel, Polymorphism, Single Nucleotide, Biomarkers, Pharmacological, Polymorphism (computer science), Carcinoma, Non-Small-Cell Lung, Internal medicine, Tumor Cells, Cultured, medicine, Carcinoma, Humans, neoplasms, Genetic Association Studies, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Hematology, business.industry, General Medicine, Middle Aged, Prognosis, medicine.disease, body regions, Treatment Outcome, Chemotherapy, Adjuvant, Cytochrome P-450 CYP1B1, Female, Taxoids, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5595da0c67b8409b2e8a1b7b1b23d1Test
https://research.vumc.nl/en/publications/96018efa-575a-443a-b58a-d1486c35ebb8Test

المؤلفون: Sergio Rizzo, Marta Castiglia, Christian Rolfo, Jan P. van Meerbeeck, Giuseppe Cicero, Patrick Pauwels, Francesco Passiglia, Giuseppe Bronte, Francesca Lo Vullo, Antionio Russo, Elisa Giovannetti, Eugenio Fiorentino

المساهمون: Bronte, G, Rolfo, C, Giovannetti, E, Cicero, G, Pauwels, P, Passiglia, F, Castiglia, M, Rizzo, S, Lo Vullo, F, Fiorentino, E, Van Meerbeeck, J, Russo, A, Medical oncology laboratory, CCA - Innovative therapy

المصدر: Bronte, G, Rolfo, C, Giovannetti, E, Cicero, G, Pauwels, P, Passiglia, F, Castiglia, M, Rizzo, S, Lo Vullo, F, Fiorentino, E, van Meerbeeck, J & Russo, A 2014, ' Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects ', Critical Reviews in Oncology / Hematology, vol. 89, no. 2, pp. 300-313 . https://doi.org/10.1016/j.critrevonc.2013.08.003Test
Critical Reviews in Oncology / Hematology, 89(2), 300-313. Elsevier Ireland Ltd
Critical reviews in oncology, hematology

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Lung Neoplasms, EGFR, Erlotinib, Gefitinib, Lung cancer, NSCLC, Tyrosine kinase, Settore MED/06 - Oncologia Medica, Antineoplastic Agents, medicine.disease_cause, Erlotinib Hydrochloride, Growth factor receptor, Pharmacokinetics, Carcinoma, Non-Small-Cell Lung, Internal medicine, Humans, Medicine, Lung, Protein Kinase Inhibitors, neoplasms, business.industry, Hematology, Oncogene Addiction, medicine.disease, respiratory tract diseases, ErbB Receptors, Quinazolines, Human medicine, business, Carcinogenesis, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cd84ee94799c56934c065ab33b14bdcTest
https://research.vumc.nl/en/publications/75a54b5d-18f2-46c0-bf46-4c2f125e47dcTest